𝔖 Bobbio Scriptorium
✦   LIBER   ✦

P.5.015 - Flesinoxan treatment of Generalized Anxiety Disorder: A fixed dose, placebo-controlled trial

✍ Scribed by F. Noël; G. Stevens; D. Bradford

Book ID
119176791
Publisher
Elsevier Science
Year
1996
Tongue
English
Weight
166 KB
Volume
6
Category
Article
ISSN
0924-977X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ritanserin in the treatment of generaliz
Ritanserin in the treatment of generalized anxiety disorders: A placebo-controlled trial
✍ E. A. Pangalila-Ratu Langi; A. A. I. Jansen 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 381 KB 👁 2 views

In a double-blind trial, 22 patients treated with 5 mg b.i.d. of the selective serotonin-S2 antagonist ritanserin for 4 weeks were compared with 26 patients treated with placebo for generalized anxiety disorder (DSM 111: 300.02). Symptoms were assessed using the Hamilton Anxiety Rating Scale (HARS)

Escitalopram in the treatment of general
Escitalopram in the treatment of generalized anxiety disorder: Double-blind, placebo controlled, flexible-dose study
✍ Jonathan R.T. Davidson; Anjana Bose; Andrew Korotzer; Hongjie Zheng 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 2 views

Escitalopram has been shown in clinical trials to improve anxiety symptoms associated with depression, panic disorder, and social anxiety disorder. This study was designed to evaluate the efficacy and tolerability of escitalopram in the treatment of generalized anxiety disorder (GAD). Outpatients (1